---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-037767"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:10:53.912468+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed Q2 ARIKAYCE rev $77.2M (+18%), raises FY guide $295-305M; net loss $244.8M

## Summary
- ARIKAYCE global revenue $77.2M, 18% YoY growth, highest quarterly sales since launch.
- Full-year 2023 ARIKAYCE revenue guidance raised to $295-305M from $285-300M.
- Net loss $244.8M ($1.78/sh) vs $95.6M loss in Q2 2022; R&D costs rose due to $76.5M acquisition of Adrestia.
- Cash, equivalents, marketable securities $918M as of June 30, down from $999M at March 31.
- Upcoming catalysts: ARISE topline data Sept 2023; ASPEN Phase 3 data expected Q2 2024; TPIP interim data H2 2023.

## SEC filing metadata
- accession: 0001140361-23-037767
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036123037767/0001140361-23-037767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036123037767/brhc20056931_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-037767
- JSON: https://secwatch.observer/filing/0001140361-23-037767.json
- Plain text: https://secwatch.observer/filing/0001140361-23-037767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.